Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer

Citations Over TimeTop 1% of 2014 papers

Abstract

Metastatic prostate cancer (PCa) is still an incurable disease. Long non-coding RNAs (lncRNAs) may be an overlooked source of cancer biomarkers and therapeutic targets. We therefore performed RNA sequencing on paired metastatic/non-metastatic PCa xenografts derived from clinical specimens. The most highly up-regulated transcript was LOC728606, a lncRNA now designated PCAT18. PCAT18 is specifically expressed in the prostate compared to 11 other normal tissues (p2). The PES was significantly associated with androgen receptor (AR) signalling. Accordingly, AR activation dramatically up-regulated PCAT18 expression in vitro and in vivo. PCAT18 silencing significantly (p<0.001) inhibited PCa cell proliferation and triggered caspase 3/7 activation, with no effect on non-neoplastic cells. PCAT18 silencing also inhibited PCa cell migration (p<0.01) and invasion (p<0.01). These results position PCAT18 as a potential therapeutic target and biomarker for metastatic PCa.

Related Papers

• → SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4(2023)62 cited
• → Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway(2018)77 cited
• → Long Non-Coding RNA (lncRNA) RAMS11 Promotes Metastatis and Cell Growth of Prostate Cancer by CBX4 Complex Binding to Top2α(2021)12 cited
• → Role and correlation of exosomes and integrins in bone metastasis of prostate cancer(2022)7 cited
• → Targeting Prostate Cancer Metastasis(2015)